Expected to be completed by September 2021, the University of Hong Kong is currently conducting a Phase II study to determine the safety of using clofazimine when combined with interferon beta-1b (an immunosuppressive drug used to reduce relapse-remitting symptoms for disease like multiple sclerosis).

For each trial, patients who have tested positive will be randomly assigned to one of three groups. The first group will be in a three-day course with one daily dose of interferon beta-1b for all three days, along with two doses of clofazimine on day one and one dose of clofazimine on day one and two daily doses of clofazimine on day two. The second group will be in a three-day course of two doses of clofazimine on day one and one dose of clofazimine on days two and three. The third group will be the control group and will only receive standard care throughout the three days.